Niki BioSolutions, Inc. in brief
Niki BioSolutions, Inc. is a listed company in the Biotechnology industry, based in the UK. It was founded in 2010. Its last known market value was $6 M (March 2026); there is no current figure. Its shares trade under the symbol NIKI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Niki BioSolutions, Inc.
Aptorum Group is a Pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. It is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases, woman health and other disease areas. The headquarters is in UK.
Niki BioSolutions, Inc. timeline
- 2010
- 🏁· approximateFounded
- 2018
- 🔔· approximateInitial public offering on Nasdaq
Events of Niki BioSolutions, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in UK: #367 (Jan 2020) · #631 (Jan 2021) · #1,165 (Jan 2022) · #1,119 (Dec 2022) · #1,264 (Jul 2023) · #1,154 (Jan 2024) · #30 (Mar 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -5.9%
- Liabilities / assets
- 26.2%
- Net debt
- $-5M
- Revenue growth
- -66.9%
- R&D / revenue
- 1209.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | — | $-1M | — |
| Dec 2024 | — | — | — | $-4M | — |
| Dec 2023 | $0M | -66.9% | — | $-3M | -655.8% |
| Dec 2022 | $1M | -15.6% | — | $-10M | -753.8% |
| Dec 2021 | $2M | — | — | $-25M | -1626.6% |
| Dec 2020 | — | — | — | $5M | — |
| Dec 2019 | — | — | — | $-20M | — |
| Dec 2018 | — | — | — | $-15M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-2M | — | — | $-0.19 | — |
| Dec 2024 | $-1M | — | — | $-0.78 | — |
| Dec 2023 | $-8M | $0M | $-8M | $-0.62 | — |
| Dec 2022 | $-12M | $0M | $-13M | $-2.75 | — |
| Dec 2021 | $-15M | $0M | $-15M | $-7.15 | — |
| Dec 2020 | $-16M | $0M | $-16M | $2.00 | — |
| Dec 2019 | $-13M | $1M | $-14M | $-0.64 | — |
| Dec 2018 | $-10M | $6M | $-16M | $-0.53 | — |
Annual results
- Revenue
- —
- Operating income
- —
- Net income
- $-1 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $19 M
- Total liabilities
- $5 M
- Total equity
- $23 M
As of December-2025
Top 3 institutional investors in Niki BioSolutions, Inc.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | HRT Financial LP | 15,462 | New | $0 M | Nov 13, 2026 |
| 2 | UBS Group AG | 2,198 | New | $0 M | Nov 10, 2026 |
| 3 | Jpmorgan Chase & Co | 2 | New | $0 M | Nov 12, 2026 |
Insider trading at Niki BioSolutions, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Alidad MireskandariPresident & COO | Option exercise | +20,000 | — | — | 20,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Niki BioSolutions, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-07-17 23:50 UTC, code D, resumed 04:00 UTC
- 2025-10-10 13:54 UTC, code LUDP, resumed 13:59 UTC
- 2025-08-21 13:54 UTC, code LUDP, resumed 13:59 UTC
- 2025-07-16 14:39 UTC, code LUDP, resumed 14:44 UTC
- 2025-07-16 14:02 UTC, code LUDP, resumed 14:12 UTC
Fails to deliver
- : 120 shares at $4.72
- : 1,133 shares at $0.82
- : 2,831 shares at $0.81
- : 3,640 shares at $0.83
- : 8,920 shares at $0.87
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Niki BioSolutions, Inc. scorecard#
Passes 0 of the 8 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.19 vs -0.78Diluted EPS -0.19 in fiscal 2025 against -0.78 the year before (report's currency).
- ✗Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against $5 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-6.2%-6.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.78 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year34.8%Diluted shares up 34.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Niki BioSolutions, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | 431−66.7%100% | 1,296−15.9%100% | 1,542—100% | — | — | — | |
| Cost of revenue | — | — | 421−65.4%97.6% | 1,216−16.7%93.8% | 1,460—94.7% | — | — | — | |
| Research and development | 353−83.9%— | 2,195−57.8%— | 5,198−43.6%1205% | 9,220−15.2%711% | 10,870−6.2%705% | 11,587+67.0%— | 6,939+124%— | 3,101—— | |
| General and administrative | 573−14.4%— | 669−65.3%— | 1,931−63.0%448% | 5,220−3.5%403% | 5,409+11.5%351% | 4,853−34.2%— | 7,373+49.9%— | 4,920—— | |
| Operating expenses | — | — | 31−99.8%7.2% | 18,805−9.4%1451% | 20,749−2.1%1346% | 21,187+13.1%— | 18,734+74.9%— | 10,712—— | |
| Total costs and expenses | — | 3,941−64.7%— | 11,156−40.7%2586% | 18,805−9.4%1451% | 20,749—1346% | — | — | — | |
| Other non-operating income (expense) | 441—— | −217−103%— | 6,383+6.7%1480% | 5,984—462% | −7,907−131%−513% | 25,196—— | −1,918—— | −4,806—— | |
| Income before tax | −1,376—— | −4,158—— | −4,341—−1006% | — | — | — | — | — | |
| Income from continuing operations | −1,376—— | −4,158—— | −4,341—−1006% | — | — | — | — | — | |
| Net income including minority interests | −1,376—— | −4,158—— | −4,341—−1006% | −11,525—−889% | −27,114−651%−1759% | 4,920—— | −20,117—— | −15,134—— | |
| Minority interests' share of net income | −13−112%— | 110—— | −1,516—−352% | −1,726—−133% | −2,066−196%−134% | 2,147+50.1%— | 1,430r−1,430+372%— | 303r−303—— | |
| Net income attributable to shareholders | −1,363—— | −4,268—— | −2,825—−655% | −9,800r−11,525—−756% | −25,048r−27,114−609%−1625% | 4,920r6,311—— | −20,117r−18,687—— | −14,832—— | |
| Earnings per share, basic | -0.19—— | -0.78—— | -0.62—— | -2.75—— | -7.15r-0.71−452%— | 2.03r0.20—— | -0.64—— | -0.53—— | |
| Earnings per share, diluted | -0.19—— | -0.78—— | -0.62—— | -2.75—— | -7.15r-0.71−458%— | 2.00r0.20—— | -0.64—— | -0.53—— | |
| Shares, weighted average (basic) | 7.4+34.8%— | 5.5+20.6%— | 4.5+26.7%— | 3.6+1.9%— | 3.5r35+12.5%— | 3.1r31−89.3%— | 29+3.9%— | 28—— | |
| Shares, weighted average (diluted) | 7.4+34.8%— | 5.5+20.6%— | 4.5+26.7%— | 3.6+1.9%— | 3.5r35+11.1%— | 3.2r32−89.1%— | 29+3.9%— | 28—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 3,453+295%18.5% | 874−56.4%5.4% | 2,005+6.5%9.7% | 1,883−76.8%9.0% | 8,131+133%37.1% | 3,495−32.6%7.9% | 5,189−56.8%21.7% | 12,007—26.6% | |
| Short-term investments | — | — | — | 102−56.7%0.5% | 237—1.1% | — | 1,063+4.8%4.4% | 1,014—2.3% | |
| Receivables | — | — | 48−72.6%0.2% | 174+122%0.8% | 79+26.5%0.4% | 62+53.5%0.1% | 41+1334%0.2% | 2.8—0.0% | |
| Inventory | — | — | — | 28−22.5%0.1% | 36−8.6%0.2% | 39+14.5%0.1% | 34+11.6%0.1% | 31—0.1% | |
| Other current assets | 140+63.7%0.7% | 85−79.8%0.5% | 422−43.3%2.0% | 744+25.4%3.6% | 593−57.0%2.7% | 1,379+27.8%3.1% | 1,079—4.5% | — | |
| Current assets | 3,593+274%19.2% | 960−61.2%5.9% | 2,476−65.0%12.0% | 7,068−44.3%33.9% | 12,688−62.3%57.9% | 33,657+319%76.1% | 8,033−72.0%33.5% | 28,723—63.7% | |
| Property, plant and equipment | — | — | 1,664−41.1%8.1% | 2,825−24.3%13.5% | 3,731−20.4%17.0% | 4,686−33.9%10.6% | 7,093+66.5%29.6% | 4,261—9.5% | |
| Right-of-use (leased) assets | — | — | 182−47.5%0.9% | 347+125%1.7% | 154−71.8%0.7% | 547—1.2% | — | — | |
| Other intangible assets | — | — | 147−80.4%0.7% | 753−14.5%3.6% | 880−8.8%4.0% | 965−26.4%2.2% | 1,312−6.9%5.5% | 1,410—3.1% | |
| Investments in associates | — | — | 77—0.4% | 0—0.0% | 0—0.0% | — | — | — | |
| Long-term investments | 15,0990.0%80.8% | 15,099−6.2%93.6% | 16,099+65.2%78.0% | 9,745—46.7% | — | — | — | — | |
| Total assets | 18,691+15.9%100% | 16,130−21.9%100% | 20,640−1.1%100% | 20,867−4.7%100% | 21,907−50.5%100% | 44,231+84.6%100% | 23,954−46.9%100% | 45,075—100% | |
| Accounts payable | 1,072+16.7%5.7% | 919−51.5%5.7% | 1,894−69.3%9.2% | 6,167+47.8%29.6% | 4,173+28.8%19.0% | 3,241+25.3%7.3% | 2,587—10.8% | — | |
| Current liabilities | 4,594+5.9%24.6% | 4,339+107%26.9% | 2,099−83.2%10.2% | 12,503+186%59.9% | 4,377+13.1%20.0% | 3,869+44.6%8.7% | 2,675−78.0%11.2% | 12,185—27.0% | |
| Long-term debt | — | — | — | 130−56.2%0.6% | 2960.0%1.4% | 296+0.5%0.7% | 295−91.4%1.2% | 3,417—7.6% | |
| Lease liabilities (non-current) | — | 14−85.7%0.1% | 99+223%0.5% | 31+29.1%0.1% | 24−84.6%0.1% | 155—0.4% | — | — | |
| Total liabilities | 4,900+12.6%26.2% | 4,353−17.2%27.0% | 5,257−59.7%25.5% | 13,034+196%62.5% | 4,401−27.6%20.1% | 6,079−33.2%13.7% | 9,102−26.2%38.0% | 12,329—27.4% | |
| Retained earnings | −73,793—−395% | −72,430—−449% | −68,162—−330% | −65,337—−313% | −55,538—−254% | −30,489—−68.9% | −37,556—−157% | −17,379—−38.6% | |
| Shareholders' equity | 23,115+9.4%124% | 21,135−14.9%131% | 24,846+58.1%120% | 15,712−33.4%75.3% | 23,607−43.6%108% | 41,834+156%94.6% | 16,361−50.6%68.3% | 33,114—73.5% | |
| Minority interests | −9,371—−50.1% | −9,357—−58.0% | −9,463—−45.8% | −7,879—−37.8% | −6,101—−27.9% | −3,682—−8.3% | −1,509—−6.3% | −369—−0.8% | |
| Total equity | 13,745+16.7%73.5% | 11,777−23.4%73.0% | 15,383+96.4%74.5% | 7,833−55.3%37.5% | 17,506−54.1%79.9% | 38,152+157%86.3% | 14,852−54.6%62.0% | 32,746—72.6% | |
| Total liabilities and equity | 18,691+15.9%100% | 16,130−21.9%100% | 20,640−1.1%100% | 20,867−4.7%100% | 21,907−50.5%100% | 44,231+84.6%100% | 23,954−46.9%100% | 45,075—100% | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | — | 255−77.3%— | 1,125−6.8%261% | 1,208+1.3%93.2% | 1,193−10.6%77.4% | 1,335+2.7%— | 1,300+90.5%— | 682—— | |
| Share-based compensation | — | — | 1,265−23.2%293% | 1,647−2.1%127% | 1,682+13.8%109% | 1,479−8.3%— | 1,613—— | — | |
| Cash from operating activities | −1,837—— | −1,190—— | −7,724—−1791% | −12,319—−951% | −14,652—−950% | −15,932—— | −13,383—— | −10,036—— | |
| Capital expenditure | — | — | −3.0—−0.7% | −187—−14.4% | −132—−8.5% | −161—— | −837—— | −5,647—— | |
| Intangible assets bought | — | — | — | — | −6.0—−0.4% | — | −70—— | −418—— | |
| Acquisitions, net of cash acquired | — | — | — | — | −114—−7.4% | — | — | — | |
| Cash from investing activities | — | 59−90.6%— | 625−74.4%145% | 2,445−85.2%189% | 16,507+796%1071% | 1,842—— | −108—— | −6,062—— | |
| Shares issued | 3,070—— | — | 1,576—365% | — | 4,000−77.1%259% | 17,497—— | — | 11,054—— | |
| Cash from financing activities | 4,415—— | — | 4,092−38.2%949% | 6,625+138%511% | 2,781−77.6%180% | 12,422—— | −7,323−129%— | 25,479—— | |
| Change in cash | — | — | — | −3,249−170%−251% | 4,636—301% | −1,668—— | −20,814−322%— | 9,381—— | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F/A | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How Niki BioSolutions, Inc. compares in Biotechnology
- Revenue growth-66.9% · higher than 12% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Niki BioSolutions, Inc.🇬🇧 | $6 M | — | — | -66.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Mar 8, 2026 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Niki BioSolutions, Inc.? Verify and update this profile — free
Show Niki BioSolutions, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.